Oryzon Genomics falling until 2.05-2.13?The recent capital increase may drag the stock price lower from current levels. Fib retracement 0.618 stops at 2.33 but indeed 2.125 (from back in Dec 2018) is a great support that ORY might want to test.
−0.058EUR
−3.35 MEUR
50.76 M
About ORYZON GENOMICS, S.A.
Sector
Industry
CEO
Carlos Manuel Buesa Arjol
Website
Headquarters
Barcelona
Founded
2000
ISIN
ES0167733015
FIGI
BBG000GMXR61
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. It focuses on epigenetics in various therapeutic indications, with a special emphasis on oncology and neurodegenerative disease. The firm's product pipelines include Iadademstat and Vafidemstat. The company was founded by Carlos Manuel Buesa Arjol and Tamara Maes on June 2, 2000 and is headquartered in Barcelona, Spain.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ORY is 1.894 EUR — it has decreased by 1.87% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BME exchange ORYZON GENOMICS, S.A. stocks are traded under the ticker ORY.
ORYZON GENOMICS, S.A. is going to release the next earnings report on May 3, 2024. Keep track of upcoming events with our Earnings Calendar.
ORY stock is 4.06% volatile and has beta coefficient of 0.25. Check out the list of the most volatile stocks — is ORYZON GENOMICS, S.A. there?
One year price forecast for ORYZON GENOMICS, S.A. has a max estimate of 12.000 EUR and a min estimate of 4.800 EUR.
ORY earnings for the last quarter are −0.02 EUR per share, whereas the estimation was −0.04 EUR resulting in a 55.04% surprise. The estimated earnings for the next quarter are −0.05 EUR per share. See more details about ORYZON GENOMICS, S.A. earnings.
Yes, you can track ORYZON GENOMICS, S.A. financials in yearly and quarterly reports right on TradingView.
ORY stock has fallen by 4.82% compared to the previous week, the month change is a 8.35% rise, over the last year ORYZON GENOMICS, S.A. has showed a 12.31% decrease.
ORY net income for the last quarter is −1.72 M EUR, while the quarter before that showed −1.06 M EUR of net income which accounts for −62.14% change. Track more ORYZON GENOMICS, S.A. financial stats to get the full picture.
Today ORYZON GENOMICS, S.A. has the market capitalization of 120.00 M, it has increased by 8.19% over the last week.
No, ORY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ORY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ORYZON GENOMICS, S.A. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ORYZON GENOMICS, S.A. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ORYZON GENOMICS, S.A. stock shows the sell signal. See more of ORYZON GENOMICS, S.A. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ORYZON GENOMICS, S.A. future price: according to them, ORY price has a max estimate of 12.00 EUR and a min estimate of 4.80 EUR. Read a more detailed ORYZON GENOMICS, S.A. forecast: see what analysts think of ORYZON GENOMICS, S.A. and suggest that you do with its stocks.